Marine-Derived Omega-3 Polyunsaturated Fatty Acids and Heart Failure: Current Understanding for Basic to Clinical Relevance
Open accessThe DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Abstract
Heart failure (HF) is a rapidly growing global public health problem. Since HF results in high mortality and re-hospitalization, new effective treatments are desired. Although it remains controversial, omega 3 polyunsaturated fatty acids (n-3 PUFAs), such as the eicosapentaenoic acid and docosahexaenoic acid, have been widely recognized to have benefits for HF. In a large-scale clinical trial regarding secondary prevention of HF by n-3 PUFA (GISSI-HF trial), the supplementation of n-3 PUFA significantly reduced cardiovascular mortality and hospitalization. Other small clinical studies proposed that n-3 PUFA potentially suppresses the ventricular remodeling and myocardial fibrosis, which thereby improves the ventricular systolic and diastolic function both in ischemic and non-ischemic HF. Basic investigations have further supported our understanding regarding the cardioprotective mechanisms of n-3 PUFA against HF. In these reports, n-3 PUFA has protected hearts through (1) anti-inflammatory effects, (2) intervention of cardiac energy metabolism, (3) modification of cardiac ion channels, (4) improvement of vascular endothelial response, and (5) modulation of autonomic nervous system activity. To clarify the pros and cons of n-3 PUFA on HF, we summarized recent evidence regarding the beneficial effects of n-3 PUFA on HF both from the clinical and basic studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Generally, the available data seem to support the positive impact of dietary n-3 PUFAs on blood pressure [20], congestive heart failure [25], and supplementation of more than one g/day−1 of n-3 PUFAs seem effective in lowering the risk of fatal cardiac events [21].”
From Microalgae n-3 PUFAs Production and Use in Food and Feed Industries (2021) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317 · cited 3×
“However, a recent large-scale clinical trial (REDUCE-IT; Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial) showed that a relatively high amount of n-3 PUFA supplementation (4 g/day) significantly reduced CVD events in patients with elevated serum triglyceride [16], and the beneficial effect o…”
BackgroundRovere, M. T. L., Bigger, J. T., Marcus, F. I., Mortara, A., & Schwartz, P. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11144-8 · Cited by 3,120 · cited 1×
“An impaired autonomic tone is one risk-factor of a fatal arrhythmic event and sudden cardiac death in patients with dilated cardiomyopathy [100] and ischemic cardiomyopathy [101].”
BackgroundYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516 · cited 20×
“Several prior prospective observational studies and randomized control trials proved that consumption of fish or fish oil containing n-3 PUFA decreased IHD mortality (e.g., myocardial infarction (MI) and sudden cardiac death) in patients with or without pre-diagnosed CVD [2,19,20].”
BackgroundInfluential(1999) · PubMed · Cited by 2,062
Fish Intake, Contaminants, and Human Health: Evaluating the Risks and the Benefits
Mozaffarian, D., & Rimm, E. B. (2006) · JAMA · doi:10.1001/jama.296.15.1885 · Cited by 1,966 · cited 18×
“Several prior prospective observational studies and randomized control trials proved that consumption of fish or fish oil containing n-3 PUFA decreased IHD mortality (e.g., myocardial infarction (MI) and sudden cardiac death) in patients with or without pre-diagnosed CVD [2,19,20].”
BackgroundInfluentialEpidemiology and aetiology of heart failure
Ziaeian, B., & Fonarow, G. C. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.25 · Cited by 1,878
Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance
Calder, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.010 · Cited by 1,717 · cited 2×
“Classically, eicosanoids originated from n-3 PUFA are known to enhance the production of anti-inflammatory cytokines at the site of inflammation, whereas essential n-6 PUFAs, such as AA, are considered as substrates of pro-inflammatory eicosanoids, which promote vascular permeability, leucocyte infiltration and activa…”
BackgroundFree fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120
Hirasawa, A., Tsumaya, K., Awaji, T., Katsuma, S., Adachi, T., Yamada, M., Sugimoto, Y., Miyazaki, S., & Tsujimoto, G. (2005) · Nature Medicine · doi:10.1038/nm1168 · Cited by 1,545 · cited 1×
“GPR120, also known as a free fatty acid receptor (FFR) 4, was detected as a receptor for n-3 PUFA, regulating downstream of intra-cellular signaling [71].”
BackgroundEpidemiology of heart failure with preserved ejection fraction
Dunlay, S. M., Roger, V. L., & Redfield, M. M. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.65 · Cited by 1,534 · cited 1×
“Although it is well-known that HF preserved ejection fraction (HFpEF) accounts for up to half of all HF in developed nations [42], to the best of our knowledge, there are fewer published reports which investigate the benefits of n-3 PUFA on patients with HFpEF.”
BackgroundGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Resolvin E1 and protectin D1 activate inflammation-resolution programmes
Schwab, J. M., Chiang, N., Arita, M., & Serhan, C. N. (2007) · Nature · doi:10.1038/nature05877 · Cited by 1,184 · cited 1×
“Recently, the essential PUFA derived large class of cell signaling lipid mediators, named specialized pro-resolving mediators (SPMs; resolvins, protectins, lipoxins, and maresins) were discovered and indicated to exert the resolution of inflammatory reactions at nanomolar levels of concentration [74,75].”
BackgroundRizos, E. C., Ntzani, E. E., Bika, E., Kostapanos, M. S., & Elisaf, M. S. (2012) · JAMA · doi:10.1001/2012.jama.11374 · Cited by 960 · cited 1×
“Heterogeneity in the blood and tissue PUFA concentration: Although a previous meta-analysis reported no statistically significant relationship between n-3 PUFA consumption and CVD mortality, the variability in individual serum n-3 PUFA levels was not taken into consideration in the study [43].”
Backgroundn–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Brenna, J. T., Salem, N., Sinclair, A. J., & Cunnane, S. C. (2009) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2009.01.004 · Cited by 863 · cited 3×
“EPA and DHA can be converted from ALA, and, similarly, LA is metabolized to AA via an enzymatic reaction of delta-6 desaturase in vivo, although the efficacy is limited and altered by age, gender, and individuals [17].”
BackgroundInfluentialYan, Y., Jiang, W., Spinetti, T., Tardivel, A., Castillo, R., Bourquin, C., Guarda, G., Tian, Z., Tschopp, J., & Zhou, R. (2013) · Immunity · doi:10.1016/j.immuni.2013.05.015 · Cited by 784 · cited 1×
“Basic studies also support the idea that n-3 PUFA would downregulate the pro-inflammatory pathways, such as NF-κB [65] and NLRP3 inflammasome [66], or upregulate anti-inflammatory intra-cellular signaling pathways, including peroxisome proliferator-activated receptor (PPAR) α/γ transcriptional activation [67].”
ResultHigh-Density Lipoprotein Subfractions - What the Clinicians Need to Know
Pirillo, A., Norata, G. D., & Catapano, A. L. (2013) · Cardiology · doi:10.1159/000346463 · Cited by 748
Thies, F., Garry, J. M., Yaqoob, P., Rerkasem, K., Williams, J., Shearman, C. P., Gallagher, P. J., Calder, P. C., & Grimble, R. F. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12468-3 · Cited by 739 · cited 1×
“RCTs of patients awaiting carotid endarterectomy also revealed that the supplementation of n-3 PUFA substantially increased tissue concentration of EPA and DHA, and decreased macrophage infiltration and thickened the fibrous cap in the human carotid artery [111].”
BackgroundBlood pressure response to fish oil supplementation: metaregression analysis of randomized trials
Geleijnse, J. M., Giltay, E. J., Grobbee, D. E., Donders, A. R. T., & Kok, F. J. (2002) · Journal of Hypertension · doi:10.1097/00004872-200208000-00010 · Cited by 700 · cited 1×
“01), and this anti-hypertensive effect of fish oil was obvious especially in the elderly and patients with hypertension [104].”
BackgroundDoes fish oil lower blood pressure? A meta-analysis of controlled trials.
Morris, M. C., Sacks, F., & Rosner, B. (1993) · Circulation · doi:10.1161/01.cir.88.2.523 · Cited by 686 · cited 1×
“, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are effective for the ischemic heart disease (IHD) [2,3], atrial [4] and ventricular arrhythmia [5], hypertension [6], peripheral artery disease [7], and HF [8–10].”
BackgroundSiscovick, D. S., Barringer, T. A., Fretts, A. M., Wu, J. H. Y., Lichtenstein, A. H., Costello, R. B., Kris-Etherton, P. M., Jacobson, T. A., Engler, M. B., Alger, H. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000482 · Cited by 629 · cited 2×
“The American Heart Association advisory board proposed a stronger recommendation, in which n-3 PUFA treatment in patients with HF with reduced ejection fraction (HFrEF) is recommended as class IIa and level of evidence B [29].”
BackgroundRauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del Castillo, U., Sack, R., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.948562 · Cited by 607
n–3 Fatty Acids in Cardiovascular Disease
De Caterina, R. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1008153 · Cited by 568 · cited 1×
“Of note, it is well known that the bioactive eicosanoids derived from PUFA have different reactions in terms of pro- or anti-inflammation, thrombotic activity, and vasocontractile or vasodilate reaction, depending on their parent PUFA compounds [18].”
BackgroundSchaeffer, L., Gohlke, H., Müller, M., Heid, I. M., Palmer, L. J., Kompauer, I., Demmelmair, H., Illig, T., Koletzko, B., & Heinrich, J. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl117 · Cited by 561 · cited 1×
“Genetic variants of the key enzymes in this pathway, including delta-5 and -6 desaturases (encoded by FAD1 and FAD2), are reported to correlate with increased ALA and decreased EPA (with no impact on DHA) [57].”
Backgroundn–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205409 · Cited by 510
Inflammation – Cause or Consequence of Heart Failure or Both?
Van Linthout, S., & Tschöpe, C. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0337-9 · Cited by 465 · cited 1×
“, interleukin-1β and TNF-α), which can reduce both systolic and diastolic cardiac function to advance cardiac remodeling through abnormal calcium handling in cardiomyocytes and enhancement of cardiac fibrosis via an activation of fibroblasts, are elevated both in the blood and local heart tissue of HF patients [58].”
BackgroundFish Intake and Risk of Incident Atrial Fibrillation
Mozaffarian, D., Psaty, B. M., Rimm, E. B., Lemaitre, R. N., Burke, G. L., Lyles, M. F., Lefkowitz, D., & Siscovick, D. S. (2004) · Circulation · doi:10.1161/01.cir.0000138154.00779.a5 · Cited by 456 · cited 1×
“, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are effective for the ischemic heart disease (IHD) [2,3], atrial [4] and ventricular arrhythmia [5], hypertension [6], peripheral artery disease [7], and HF [8–10].”
BackgroundMitochondrial OPA1, apoptosis, and heart failure
Chen, L., Gong, Q., Stice, J. P., & Knowlton, A. A. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp181 · Cited by 426 · cited 1×
“Mitochondrial dynamics play key roles for the pathophysiology of HF [90,91].”
BackgroundMuscle wasting and cachexia in heart failure: mechanisms and therapies
von Haehling, S., Ebner, N., dos Santos, M. R., Springer, J., & Anker, S. D. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.51 · Cited by 421 · cited 1×
“In addition, systemic inflammatory cytokines are considered one of the major causes of cachexia during HF [59,60].”
BackgroundEicosapentaenoic Acid Prevents LPS-Induced TNF-α Expression by Preventing NF-κB Activation
Zhao, Y., Joshi-Barve, S., Barve, S., & Chen, L. H. (2004) · Journal of the American College of Nutrition · doi:10.1080/07315724.2004.10719345 · Cited by 405 · cited 2×
“Basic studies also support the idea that n-3 PUFA would downregulate the pro-inflammatory pathways, such as NF-κB [65] and NLRP3 inflammasome [66], or upregulate anti-inflammatory intra-cellular signaling pathways, including peroxisome proliferator-activated receptor (PPAR) α/γ transcriptional activation [67].”
ResultMa, J., Folsom, A., Shahar, E., & Eckfeldt, J. (1995) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/62.3.564 · Cited by 364
Lipid metabolic enzymes: emerging drug targets for the treatment of obesity
Shi, Y., & Burn, P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1469 · Cited by 333 · cited 1×
“Meanwhile the bioavailability of the ethyl-ester form of n-3 PUFA is highly dependent on the presence of dietary fat, which can stimulate the release of bile salts into the small intestinal tract, because n-3 PUFA ethyl-esters requires digestion with bile salt-dependent lipase [52,53].”
BackgroundXiao, Y. F., Kang, J. X., Morgan, J. P., & Leaf, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.11000 · Cited by 332 · cited 1×
“, neonatal and adult rat ventricular myocytes), n-3 PUFA exhibited the inhibition of sodium current in a dose-dependent manner [97,98].”
BackgroundOmega‐3 Dietary Supplements and the Risk of Cardiovascular Events: A Systematic Review
Marik, P. E., & Varon, J. (2009) · Clinical Cardiology · doi:10.1002/clc.20604 · Cited by 328 · cited 20×
“Several prior prospective observational studies and randomized control trials proved that consumption of fish or fish oil containing n-3 PUFA decreased IHD mortality (e.g., myocardial infarction (MI) and sudden cardiac death) in patients with or without pre-diagnosed CVD [2,19,20].”
BackgroundInfluentialMontaigne, D., Marechal, X., Coisne, A., Debry, N., Modine, T., Fayad, G., Potelle, C., El Arid, J.-M., Mouton, S., Sebti, Y., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.008476 · Cited by 322 · cited 1×
“Mitochondrial dynamics play key roles for the pathophysiology of HF [90,91].”
BackgroundItoh, M., Suganami, T., Satoh, N., Tanimoto-Koyama, K., Yuan, X., Tanaka, M., Kawano, H., Yano, T., Aoe, S., Takeya, M., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.106.136853 · Cited by 290 · cited 1×
“PPARγ-dependent adiponectin secretion is thought to correlate with n-3 PUFA-mediated cardiac protection, and the administration of n-3 PUFA increased the circulation of adiponectin in a dose-dependent manner both in animal [62,69] and human [70] studies.”
BackgroundFish Intake and Risk of Incident Heart Failure
Mozaffarian, D., Bryson, C. L., Lemaitre, R. N., Burke, G. L., & Siscovick, D. S. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.038 · Cited by 276 · cited 2×
“In 2005, the Cardiovascular Health Study, which studied 4738 elderly US patients for 12 years, reported that fish consumption (broiled or baked, but not fried, tuna or other fish) was associated with a lower incidence of HF [8].”
BackgroundYamagishi, K., Iso, H., Date, C., Fukui, M., Wakai, K., Kikuchi, S., Inaba, Y., Tanabe, N., & Tamakoshi, A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.018 · Cited by 275
Biochemical effects of a diet containing foods enriched with n−3 fatty acids
Mantzioris, E., Cleland, L. G., Gibson, R. A., Neumann, M. A., Demasi, M., & James, M. J. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.1.42 · Cited by 257
Serhan, C. N. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.03.001 · Cited by 257 · cited 1×
“Recently, the essential PUFA derived large class of cell signaling lipid mediators, named specialized pro-resolving mediators (SPMs; resolvins, protectins, lipoxins, and maresins) were discovered and indicated to exert the resolution of inflammatory reactions at nanomolar levels of concentration [74,75].”
BackgroundBioavailability of marine n-3 fatty acid formulations
Dyerberg, J., Madsen, P., Møller, J. M., Aardestrup, I., & Schmidt, E. B. (2010) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2010.06.007 · Cited by 256 · cited 1×
“Regarding bioavailability, the free forms of n-3 PUFA seem to provide better CVD outcomes than the ethyl-ester forms [54,55].”
BackgroundChristensen, J. H., Gustenhoff, P., Korup, E., Aaroe, J., Toft, E., Moller, T., Rasmussen, K., Dyerberg, J., & Schmidt, E. B. (1996) · BMJ · doi:10.1136/bmj.312.7032.677 · Cited by 244 · cited 1×
“Some clinical studies revealed that n-3 PUFA supplementation improved heart rate variability (an index of autonomic tone) in patients with ischemic and non-ischemic cardiomyopathy [39,40,102,103].”
BackgroundKain, V., Ingle, K. A., Colas, R. A., Dalli, J., Prabhu, S. D., Serhan, C. N., Joshi, M., & Halade, G. V. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.04.003 · Cited by 235 · cited 1×
“Other rodent studies investigating the post-MI rodent heart revealed that the exogenous delivery of resolvins reduced infarction size [77] and excessive inflammation and fibrosis [78], leading to improved cardiac function [78].”
BackgroundEffect of fish oil on arrhythmias and mortality: systematic review.
Leon, H., Shibata, M. C., Sivakumaran, S., Dorgan, M., Chatterley, T., & Tsuyuki, R. T. (2008) · BMJ · doi:10.1136/bmj.a2931 · Cited by 223 · cited 17×
“Several prior prospective observational studies and randomized control trials proved that consumption of fish or fish oil containing n-3 PUFA decreased IHD mortality (e.g., myocardial infarction (MI) and sudden cardiac death) in patients with or without pre-diagnosed CVD [2,19,20].”
BackgroundInfluentialNodari, S., Triggiani, M., Campia, U., Manerba, A., Milesi, G., Cesana, B. M., Gheorghiade, M., & Dei Cas, L. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.017 · Cited by 217 · cited 2×
“[24] 2011 SC, RDM, DB, PC 67; n-3 PUFA 66; placebo (olive oil) Italy 5 g/day for 1mon 2 g/day for 11mon Mean age; 62 y (18 to 75), NYHA; I 14%, II 86% Mean EF 36% 1 years Increased LVEF and Peak VO2.”
BackgroundSerum Fatty Acids and the Risk of Coronary Heart Disease
Simon, J. A., Hodgkins, M. L., Browner, W. S., Neuhaus, J. M., Bernert, J. T., & Hulley, S. B. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117662 · Cited by 212 · cited 5×
“Several prior prospective observational studies and randomized control trials proved that consumption of fish or fish oil containing n-3 PUFA decreased IHD mortality (e.g., myocardial infarction (MI) and sudden cardiac death) in patients with or without pre-diagnosed CVD [2,19,20].”
BackgroundInfluentialPepe, S., & McLennan, P. L. (2002) · Circulation · doi:10.1161/01.cir.0000015604.88808.74 · Cited by 208 · cited 1×
“Previous animal studies revealed that the dietary n-3 PUFA intake altered the mitochondrial membrane phospholipid composition in cardiomyocytes, which led to a decrease in myocardial oxygen consumption without loss of ventricular power generation [82,83].”
ResultDavidson, M. H., Johnson, J., Rooney, M. W., Kyle, M. L., & Kling, D. F. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.01.002 · Cited by 191 · cited 1×
“Meanwhile the bioavailability of the ethyl-ester form of n-3 PUFA is highly dependent on the presence of dietary fat, which can stimulate the release of bile salts into the small intestinal tract, because n-3 PUFA ethyl-esters requires digestion with bile salt-dependent lipase [52,53].”
BackgroundVirtanen, J. K., Mursu, J., Voutilainen, S., & Tuomainen, T.-P. (2009) · Circulation · doi:10.1161/circulationaha.109.852657 · Cited by 189 · cited 1×
“It is well known that the risk reduction of CVD depends on n-3 PUFA blood concentration [44], and an inverse correlation with the blood n-3 PUFA profiles has been reported in IHD [47,48], arrhythmia [49], peripheral artery disease [50], and HF [21,51].”
BackgroundDuda, M. K., O'Shea, K. M., Tintinu, A., Xu, W., Khairallah, R. J., Barrows, B. R., Chess, D. J., Azimzadeh, A. M., Harris, W. S., Sharov, V. G., et al. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvn310 · Cited by 186 · cited 2×
“, thromboxane B2), and prevented abnormal LV remodeling [62].”
BackgroundMitochondrial fusion and division: Regulation and role in cell viability
Benard, G., & Karbowski, M. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.12.012 · Cited by 184 · cited 1×
“, dynamin related protein 1 (Drp1), mitochondrial fission 1 protein, and mitochondrial fission factor) proteins are involved in the regulation of mitochondrial dynamics [92].”
BackgroundMozaffarian, D., Lemaitre, R. N., King, I. B., Song, X., Spiegelman, D., Sacks, F. M., Rimm, E. B., & Siscovick, D. S. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-3-201108020-00006 · Cited by 182
London, B., Albert, C., Anderson, M. E., Giles, W. R., Van Wagoner, D. R., Balk, E., Billman, G. E., Chung, M., Lands, W., Leaf, A., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.712984 · Cited by 174
Heydari, B., Abdullah, S., Pottala, J. V., Shah, R., Abbasi, S., Mandry, D., Francis, S. A., Lumish, H., Ghoshhajra, B. B., Hoffmann, U., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.019949 · Cited by 171 · cited 5×
“Study or Author/Reference Year of Publication Study Design Number of Patients Region n-3 PUFA Baseline Patient Background Follow Up Outcomes Interpretation OMEGA-REMODEL [36] 2016 MC, RDM, DB, PC 180; n-3 PUFA 178; placebo (corn oil) USA 4 g/day Mean age; 59 y, male 80%, NYHA; I 91%, II 8%, III 1%, Mean EF 54% 6 month…”
BackgroundMethodInfluentialEndo, J., Sano, M., Isobe, Y., Fukuda, K., Kang, J. X., Arai, H., & Arita, M. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20132011 · Cited by 170 · cited 1×
“, 18-hydroxyeicosapentaenoic acid) administration in a pressure overload HF model mouse was also reported to ameliorate cardiac inflammation and fibrosis and preserve systolic function [79].”
BackgroundResolvin E1 protects the rat heart against reperfusion injury
Keyes, K. T., Ye, Y., Lin, Y., Zhang, C., Perez-Polo, J. R., Gjorstrup, P., & Birnbaum, Y. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01057.2009 · Cited by 168 · cited 1×
“Other rodent studies investigating the post-MI rodent heart revealed that the exogenous delivery of resolvins reduced infarction size [77] and excessive inflammation and fibrosis [78], leading to improved cardiac function [78].”
BackgroundThe Adrenergic-Fatty Acid Load in Heart Failure
Opie, L. H., & Knuuti, J. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.024 · Cited by 167 · cited 1×
“Excessive free FA exposure to cardiomyocytes causes uncoupled mitochondrial respiration and reactive oxygen species (ROS) production [87], which thereby causes energy depletion and further impairs contraction in the failing heart [88].”
BackgroundFauchier, L., Babuty, D., Cosnay, P., & Fauchier, J. P. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00021-2 · Cited by 159 · cited 1×
“An impaired autonomic tone is one risk-factor of a fatal arrhythmic event and sudden cardiac death in patients with dilated cardiomyopathy [100] and ischemic cardiomyopathy [101].”
BackgroundMatsumoto, M., Sata, M., Fukuda, D., Tanaka, K., Soma, M., Hirata, Y., & Nagai, R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.07.023 · Cited by 158 · cited 1×
“reported that EPA significantly suppressed the development of atherosclerotic lesions in atherosclerosis-prone mice with reduced production of matrix metalloproteinases released by macrophages in a PPARα-dependent fashion [110].”
BackgroundEicosapentaenoic Acid Enhances Nitric Oxide Production by Cultured Human Endothelial Cells
Okuda, Y., Kawashima, K., Sawada, T., Tsurumaru, K., Asano, M., Suzuki, S., Soma, M., Nakajima, T., & Yamashita, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6328 · Cited by 142 · cited 1×
“The n-3 PUFA has been reported to release NO from vascular endothelial cells both in vivo [105] and in vitro [106].”
BackgroundMoertl, D., Hammer, A., Steiner, S., Hutuleac, R., Vonbank, K., & Berger, R. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.02.011 · Cited by 132 · cited 3×
“[33] 2011 SC, RDM, DB, PC, 3-arm 14; n-3 PUFA (1g/d) 13; n-3 PUFA (4g/d) 16; placebo Austria 1 g/day or 4 g/day Mean age; 58 y, male 86%, NYHA; III 91%, IV 9%, Mean EF; 24% 3 months Increased LVEF (4 g/day; +5%, 1 g/day; +3%).”
BackgroundInfluentialSplenic leukocytes define the resolution of inflammation in heart failure
Halade, G. V., Norris, P. C., Kain, V., Serhan, C. N., & Ingle, K. A. (2018) · Science Signaling · doi:10.1126/scisignal.aao1818 · Cited by 132 · cited 1×
“predominantly derived from DHA to resolve the local acute inflammatory reaction [76].”
BackgroundFish oils produce anti-inflammatory effects and improve body weight in severe heart failure
Mehra, M. R., Lavie, C. J., Ventura, H. O., & Milani, R. V. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.005 · Cited by 122 · cited 2×
“A small randomized double-blind trial, which was conducted in a placebo-controlled study with 14 symptomatic HF patients (NYHA III or IV), revealed that a high-dose n-3 PUFA (8 g/day) intake for 18 weeks significantly decreased the lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-α) released from patients’…”
BackgroundInhibition of cardiac sodium currents in adult rat myocytes by n‐3 polyunsaturated fatty acids
Leifert, W. R., McMurchie, E. J., & Saint, D. A. (1999) · The Journal of Physiology · doi:10.1111/j.1469-7793.1999.00671.x · Cited by 119 · cited 1×
“, neonatal and adult rat ventricular myocytes), n-3 PUFA exhibited the inhibition of sodium current in a dose-dependent manner [97,98].”
BackgroundDUDA, M., OSHEA, K., LEI, B., BARROWS, B., AZIMZADEH, A., MCELFRESH, T., HOIT, B., KOP, W., & STANLEY, W. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2007.07.002 · Cited by 108
Schiano, V., Laurenzano, E., Brevetti, G., Maio, J. I. D., Lanero, S., Scopacasa, F., & Chiariello, M. (2008) · Clinical Nutrition · doi:10.1016/j.clnu.2007.11.007 · Cited by 107 · cited 1×
“, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are effective for the ischemic heart disease (IHD) [2,3], atrial [4] and ventricular arrhythmia [5], hypertension [6], peripheral artery disease [7], and HF [8–10].”
BackgroundSkeletal muscle inflammation and atrophy in heart failure
Lavine, K. J., & Sierra, O. L. (2017) · Heart Failure Reviews · doi:10.1007/s10741-016-9593-0 · Cited by 104 · cited 1×
“In addition, systemic inflammatory cytokines are considered one of the major causes of cachexia during HF [59,60].”
BackgroundManagement of Arrhythmias in Heart Failure
Masarone, D., Limongelli, G., Rubino, M., Valente, F., Vastarella, R., Ammendola, E., Gravino, R., Verrengia, M., Salerno, G., & Pacileo, G. (2017) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd4010003 · Cited by 104 · cited 1×
“Patients with HF are highly comorbid with arrhythmia, and the incidence of arrhythmia certainly worsens the rate of mortality of HF [94].”
BackgroundOmega-3 Fatty Acid Blood Levels: Clinical Significance and Controversy
Superko, H. R., Superko, S. M., Nasir, K., Agatston, A., & Garrett, B. C. (2013) · Circulation · doi:10.1161/circulationaha.113.002731 · Cited by 100 · cited 2×
“reported that a fixed-dose n-3 PUFA administration exhibited significant individual variation in the blood n-3 PUFA levels [44], whereas, in general, dietary intake of n-3 PUFA is closely associated with its blood levels [45,46].”
BackgroundDiet-induced Obesity Up-regulates the Abundance of GPR43 and GPR120 in a Tissue Specific Manner
Cornall, L. M., Mathai, M. L., Hryciw, D. H., & McAinch, A. J. (2011) · Cellular Physiology and Biochemistry · doi:10.1159/000335820 · Cited by 94 · cited 5×
“In addition, the activation of FFR4 by n-3 PUFA further stimulated endothelial nitric oxide synthase (eNOS) and promoted intracellular nitric oxide (NO), which leads to the suppression of TGF-β1 induced smad2/3 nuclear translocation and inhibition of pro-fibrotic gene transcription.”
BackgroundInfluentialOffman, E., Marenco, T., Ferber, S., Johnson, J., Kling, D., Curcio, D., & Davidson, M. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50464 · Cited by 92
Khairallah, R. J., Sparagna, G. C., Khanna, N., O’Shea, K. M., Hecker, P. A., Kristián, T., Fiskum, G. M., Rosiers, C. D., Polster, B. M., & Stanley, W. C. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.05.007 · Cited by 87
Serum free fatty acid pattern and risk of myocardial infarction: a case‐control study
YLI‐JAMA, P., MEYER, H. E., RINGSTAD, J., & PEDERSEN, J. I. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00922.x · Cited by 85 · cited 1×
“, palmitate and stearate) are reported as the main components of serum free FAs [89].”
BackgroundLevitan, E. B., Wolk, A., & Mittleman, M. A. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp111 · Cited by 84
Fish Intake and the Risk of Incident Heart Failure: The Women's Health Initiative
Belin, R. J., Greenland, P., Martin, L., Oberman, A., Tinker, L., Robinson, J., Larson, J., Van Horn, L., & Lloyd-Jones, D. (2011) · Circulation: Heart Failure · doi:10.1161/circheartfailure.110.960450 · Cited by 83 · cited 2×
“The following two large-scale studies in the US (Woman’s Health Initiative and Physicians’ Health study) exhibited an inverse correlation between fish consumption and HF incidence [9,22], and a Japanese large cohort study revealed that total fish consumption including “Tempura fried fish” and regular n-3 PUFA intake s…”
BackgroundGhio, S., Scelsi, L., Latini, R., Masson, S., Eleuteri, E., Palvarini, M., Vriz, O., Pasotti, M., Gorini, M., Marchioli, R., et al. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq172 · Cited by 82
Nodari, S., Metra, M., Milesi, G., Manerba, A., Cesana, B. M., Gheorghiade, M., & Cas, L. D. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6142-7 · Cited by 80 · cited 2×
“Some clinical studies revealed that n-3 PUFA supplementation improved heart rate variability (an index of autonomic tone) in patients with ischemic and non-ischemic cardiomyopathy [39,40,102,103].”
BackgroundSwann, P. G., Venton, D. L., & Le Breton, G. C. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)80137-1 · Cited by 79 · cited 1×
“The n-3 PUFA is reported to suppress the synthesis of platelet-derived thromboxane A2 (TXA2), which causes platelet aggregation and vasoconstriction [108], and to increase the plasminogen activator inhibitor-1 with reduction of fibrinogen [109].”
BackgroundLeng, G. C., Horrobin, D. F., Fowkes, F. G., Smith, F. B., Lowe, G. D., Donnan, P. T., & Ells, K. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.3.471 · Cited by 76 · cited 1×
“It is well known that the risk reduction of CVD depends on n-3 PUFA blood concentration [44], and an inverse correlation with the blood n-3 PUFA profiles has been reported in IHD [47,48], arrhythmia [49], peripheral artery disease [50], and HF [21,51].”
BackgroundFrequency and Type of Seafood Consumed Influence Plasma (n-3) Fatty Acid Concentrations
Chung, H., Nettleton, J. A., Lemaitre, R. N., Barr, R. G., Tsai, M. Y., Tracy, R. P., & Siscovick, D. S. (2008) · The Journal of Nutrition · doi:10.3945/jn.108.089631 · Cited by 76 · cited 1×
“reported that a fixed-dose n-3 PUFA administration exhibited significant individual variation in the blood n-3 PUFA levels [44], whereas, in general, dietary intake of n-3 PUFA is closely associated with its blood levels [45,46].”
BackgroundZhao, Y., Shao, L., Teng, L., Hu, B., Luo, Y., Yu, X., Zhang, D., & Zhang, H. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700619 · Cited by 74 · cited 1×
“[31] 2009 MC, RDM, DB, PC 38; n-3 PUFA 37; placebo China 2 g/day Mean age; 73 y, male 73%, NYHA; II 37%, III 63%, Mean EF; 31% 3 months Reduced in serum NT-proBNP (p < 0.”
Dietary Fat Intake and Proinflammatory Cytokine Levels in Patients With Heart Failure
Lennie, T. A., Chung, M. L., Habash, D., & Moser, D. K. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.06.434 · Cited by 73
Tominaga, H., Katoh, H., Odagiri, K., Takeuchi, Y., Kawashima, H., Saotome, M., Urushida, T., Satoh, H., & Hayashi, H. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01307.2007 · Cited by 70 · cited 1×
“Excessive free FA exposure to cardiomyocytes causes uncoupled mitochondrial respiration and reactive oxygen species (ROS) production [87], which thereby causes energy depletion and further impairs contraction in the failing heart [88].”
BackgroundSelf-citationWilk, J. B., Tsai, M. Y., Hanson, N. Q., Gaziano, J. M., & Djoussé, L. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.042671 · Cited by 69 · cited 2×
“The following two large-scale studies in the US (Woman’s Health Initiative and Physicians’ Health study) exhibited an inverse correlation between fish consumption and HF incidence [9,22], and a Japanese large cohort study revealed that total fish consumption including “Tempura fried fish” and regular n-3 PUFA intake s…”
BackgroundCardiac Insulin Resistance in Heart Failure: The Role of Mitochondrial Dynamics
Saotome, M., Ikoma, T., Hasan, P., & Maekawa, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143552 · Cited by 68 · cited 1×
“Alteration of energetic substrate utilization in myocardium and modification of its intra-cellular signaling pathway also play important roles for the pathogenesis and progression of HF [81].”
BackgroundSelf-citationGani, O. A. B. S. M., & Sylte, I. (2008) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2008.04.008 · Cited by 67 · cited 1×
“Basic studies also support the idea that n-3 PUFA would downregulate the pro-inflammatory pathways, such as NF-κB [65] and NLRP3 inflammasome [66], or upregulate anti-inflammatory intra-cellular signaling pathways, including peroxisome proliferator-activated receptor (PPAR) α/γ transcriptional activation [67].”
ResultWu, Y., Zhang, C., Dong, Y., Wang, S., Song, P., Viollet, B., & Zou, M.-H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035508 · Cited by 64 · cited 1×
“The n-3 PUFA has been reported to release NO from vascular endothelial cells both in vivo [105] and in vitro [106].”
BackgroundChiurchiù, V., Leuti, A., Saracini, S., Fontana, D. O., Finamore, P., Giua, R., Padovini, L., Incalzi, R. A., & Maccarrone, M. (2018) · The FASEB Journal · doi:10.1096/fj.201801017r · Cited by 62 · cited 1×
“A recent clinical study revealed that plasma resolvin D1 levels were markedly decreased in patients with chronic HF compared with healthy subjects, suggesting a defect of resolvin biosynthesis in HF conditions [80].”
BackgroundEclov, J. A., Qian, Q., Redetzke, R. A., Chen, Q., Wu, S. C., Healy, C. L., Ortmeier, S. B., Harmon, E. B., Shearer, G. C., & O’Connell, T. D. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m062034 · Cited by 61 · cited 2×
“revealed that the expression of FFR4 was markedly higher than other subtypes of FFRs in cardiomyocytes as well as fibroblasts isolated from mice [72].”
BackgroundOikonomou, E., Vogiatzi, G., Karlis, D., Siasos, G., Chrysohoou, C., Zografos, T., Lazaros, G., Tsalamandris, S., Mourouzis, K., Georgiopoulos, G., et al. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.04.017 · Cited by 61 · cited 2×
“[38] 2019 SC, DB, PC, cross over 15 vs 16; n-3 PUFA/placebo (olive oil, cross-over with 6 weeks wash-out period) Greece 2 g/day Mean age; 67 y (18 to 80), NYHA; II 65%, III 35%, Mean EF 29%, 2 months Increased LVEF Reduced global longitudinal strain, E/e’ ratio, hsCRP, ST2 levels, FMD % increase n-3 PUFA improved infl…”
BackgroundKhairallah, R. J., O’Shea, K. M., Brown, B. H., Khanna, N., Rosiers, C. D., & Stanley, W. C. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170605 · Cited by 57
Dijkstra, S. C., Brouwer, I. A., van Rooij, F. J. A., Hofman, A., Witteman, J. C. M., & Geleijnse, J. M. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp126 · Cited by 55 · cited 1×
“Rotterdam study [25] 2009 Nederland 11.”
Chrysohoou, C. A., Metallinos, G., Georgiopoulos, G., Mendrinos, D., Papanikolaou, A., Magkas, N., Pitsavos, C. E., Vyssoulis, G. P., Stefanadis, C., & Tousoulis, D. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2016.01.005 · Cited by 55 · cited 1×
“[37] 2016 SC, RDM, OL, PRS 101; n-3 PUFA 95; without n-3 PUFA (no placebo) Greece 1 g/day Mean age; 63y, male 83%, NYHA; I-III, Median EF; 28% 6 months Reduce ESLVD, LAEF, TDI Etv/Atv and BNP n-3 PUFA improved LV diastolic function and decreased BNP levels”
BackgroundRadaelli, A., Cazzaniga, M., Viola, A., Balestri, G., Janetti, M. B., Signorini, M. G., Castiglioni, P., Azzellino, A., Mancia, G., & Ferrari, A. U. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.073 · Cited by 52 · cited 2×
“Some clinical studies revealed that n-3 PUFA supplementation improved heart rate variability (an index of autonomic tone) in patients with ischemic and non-ischemic cardiomyopathy [39,40,102,103].”
BackgroundFatty fish, marine ω-3 fatty acids and incidence of heart failure
Levitan, E. B., Wolk, A., & Mittleman, M. A. (2010) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2010.50 · Cited by 52
Hara, M., Sakata, Y., Nakatani, D., Suna, S., Usami, M., Matsumoto, S., Hamasaki, T., Doi, Y., Nishino, M., Sato, H., et al. (2013) · Circulation Journal · doi:10.1253/circj.cj-12-0875 · Cited by 48 · cited 1×
“It is well known that the risk reduction of CVD depends on n-3 PUFA blood concentration [44], and an inverse correlation with the blood n-3 PUFA profiles has been reported in IHD [47,48], arrhythmia [49], peripheral artery disease [50], and HF [21,51].”
BackgroundKohashi, K., Nakagomi, A., Saiki, Y., Morisawa, T., Kosugi, M., Kusama, Y., Atarashi, H., & Shimizu, W. (2014) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.21022 · Cited by 47
Pepe, S., & McLennan, P. L. (2007) · Journal of Nutrition · doi:10.1093/jn/137.11.2377 · Cited by 46 · cited 1×
“Previous animal studies revealed that the dietary n-3 PUFA intake altered the mitochondrial membrane phospholipid composition in cardiomyocytes, which led to a decrease in myocardial oxygen consumption without loss of ventricular power generation [82,83].”
ResultElectrophysiological Mechanisms of the Anti-arrhythmic Effects of Omega-3 Fatty Acids
Richardson, E. S., Iaizzo, P. A., & Xiao, Y. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9243-1 · Cited by 44 · cited 1×
“A number of basic experimental studies have revealed direct and/or indirect alteration in the electrophysiological behavior of plasma membrane ion channels of cardiomyocytes, such as the sodium, potassium and calcium channels, as well as the sodium-calcium exchanger [95,96].”
BackgroundEngström, K., Saldeen, A.-S., Yang, B., Mehta, J. L., & Saldeen, T. (2009) · Upsala Journal of Medical Sciences · doi:10.3109/03009730903268958 · Cited by 43
Wang, C., Xiong, B., & Huang, J. (2016) · Nutrients · doi:10.3390/nu9010018 · Cited by 42
Familial aggregation of red blood cell membrane fatty acid composition: the Kibbutzim Family Study
Lemaître, R. N., Siscovick, D. S., Berry, E. M., Kark, J. D., & Friedlander, Y. (2008) · Metabolism · doi:10.1016/j.metabol.2007.12.011 · Cited by 41 · cited 1×
“Prior familial aggregation analysis indicated the strong heritability of FA composition in the Red blood cells (RBC) membrane (up to 40%–70%) [56].”
BackgroundEffects of fish oil on some parameters of fibrinolysis and lipoprotein(a) in healthy subjects
Haglund, O., Mehta, J. L., & Saldeen, T. G. P. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90100-7 · Cited by 37 · cited 1×
“The n-3 PUFA is reported to suppress the synthesis of platelet-derived thromboxane A2 (TXA2), which causes platelet aggregation and vasoconstriction [108], and to increase the plasminogen activator inhibitor-1 with reduction of fibrinogen [109].”
BackgroundÅkesson, A., Donat-Vargas, C., Berglund, M., Glynn, A., Wolk, A., & Kippler, M. (2019) · Environment International · doi:10.1016/j.envint.2019.01.069 · Cited by 36 · cited 1×
“A recent study from a Swedish cohort revealed that the dietary intake of PCBs increased the risk of HF (up to 42%–48%), although the intake of EPA-DHA was associated with 18–29% lower risk of HF in mutually-adjusted models contrasting extreme quintiles of exposures [28].”
BackgroundLeifert, W. R., Dorian, C. L., Jahangiri, A., & McMurchie, E. J. (2001) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(01)00151-6 · Cited by 34 · cited 1×
“release by isoproterenol stimulation [99], suggesting a contribution of n-3 PUFA to suppression of arrhythmogenicity (i.”
BackgroundRovere, M. T. L., Staszewsky, L. I., Barlera, S., Maestri, R., Mezzani, A., Midi, P., Marchioli, R., Maggioni, A. P., Tognoni, G., Tavazzi, L., et al. (2012) · Heart Rhythm · doi:10.1016/j.hrthm.2012.10.035 · Cited by 33 · cited 1×
“Some clinical studies revealed that n-3 PUFA supplementation improved heart rate variability (an index of autonomic tone) in patients with ischemic and non-ischemic cardiomyopathy [39,40,102,103].”
BackgroundSakamoto, A., Saotome, M., Hasan, P., Satoh, T., Ohtani, H., Urushida, T., Katoh, H., Satoh, H., & Hayashi, H. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.01.004 · Cited by 30 · cited 1×
“We, in our previous investigation, reported that EPA activated phosphorylation of AMP-activated protein kinase (AMPK; a key enzyme for cellular energy homeostasis), altered mitochondrial morphology (relatively elongated mitochondria by suppression in Drp1) in myocardium, and thereby protected myocytes from SFA-induced…”
BackgroundSelf-citationGalvão, T. F. G., Khairallah, R. J., Dabkowski, E. R., Brown, B. H., Hecker, P. A., O’Connell, K. A., O’Shea, K. M., Sabbah, H. N., Rastogi, S., Daneault, C., et al. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00657.2012 · Cited by 27
Kojuri, J., Ostovan, M. A., Rezaian, G. R., Dialameh, P. A., Zamiri, N., Sharifkazemi, M., & Jannati, M. (2013) · Journal of Cardiovascular Disease Research · doi:10.1016/j.jcdr.2013.02.013 · Cited by 24 · cited 1×
“[34] 2013 SC, RDM, DB, PC 38; n-3 PUFA 32; placebo Iran 2 g/day Mean age; 57 y, male 60%, NYHA; II to III, Mean EF; 31% 6 months Reduced late diastolic velocity index, Tei index and plasma BNP n-3 PUFA slightly decreased plasma BNP levels and moderately improved ventricular diastolic function.”
BackgroundAberrant serum polyunsaturated fatty acids profile is relevant with acute coronary syndrome
Sakamoto, A., Saotome, M., Hosoya, N., Kageyama, S., Yoshizaki, T., Takeuchi, R. F., Murata, K., Nawada, R., Onodera, T., Takizawa, A., et al. (2015) · Heart and Vessels · doi:10.1007/s00380-015-0721-x · Cited by 13 · cited 5×
“Several prior prospective observational studies and randomized control trials proved that consumption of fish or fish oil containing n-3 PUFA decreased IHD mortality (e.g., myocardial infarction (MI) and sudden cardiac death) in patients with or without pre-diagnosed CVD [2,19,20].”
BackgroundInfluentialSelf-citationOmega–3 Fatty Acids and Ventricular Arrhythmias
Leaf, A., Kang, J. X., & Xiao, Y. (2005) · KARGER eBooks · doi:10.1159/000088226 · Cited by 11 · cited 1×
“, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are effective for the ischemic heart disease (IHD) [2,3], atrial [4] and ventricular arrhythmia [5], hypertension [6], peripheral artery disease [7], and HF [8–10].”
Background
Cited by
Algae as Food in Europe: An Overview of Species Diversity and Their Application
Mendes, M., Navalho, S., Ferreira, A., Paulino, C., Figueiredo, D., Silva, D., Gao, F., Gama, F., Bombo, G., Jacinto, R., et al. (2022) · Foods · doi:10.3390/foods11131871 · Cited by 234
Microalgae n-3 PUFAs Production and Use in Food and Feed Industries
Remize, M., Brunel, Y., Silva, J. L., Berthon, J.-Y., & Filaire, E. (2021) · Marine Drugs · doi:10.3390/md19020113 · Cited by 214
“Generally, the available data seem to support the positive impact of dietary n-3 PUFAs on blood pressure [20], congestive heart failure [25], and supplementation of more than one g/day−1 of n-3 PUFAs seem effective in lowering the risk of fatal cardiac events [21].”
BackgroundBiomaterials from the sea: Future building blocks for biomedical applications
Wan, M.-C., Qin, W., Lei, C., Li, Q.-H., Meng, M., Fang, M., Song, W., Chen, J.-H., Tay, F., & Niu, L.-N. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.04.028 · Cited by 171
“[327] with permission from the publisher; C is reproduced from Ref.”
BackgroundPatted, P. G., Masareddy, R. S., Patil, A. S., Kanabargi, R., & Bhat, C. T. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00667-5 · Cited by 149
Bilal, M., & Iqbal, H. M. N. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.02.037 · Cited by 66
Metadata
- Authors
- Sakamoto, A., Saotome, M., Iguchi, K., & Maekawa, Y.
- Affiliations
- Hamamatsu University (JP)
- Corresponding author
- Saotome, Masao
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-08-18
- Volume
- 20
- Issue
- 16
- Pages
- 4025
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6719114
- OpenAlex
- W2968977140
- Cited by
- 73
- References
- 114
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 10 · 2023: 9 · 2022: 11 · 2021: 16 · 2020: 10
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (JP16K09428, JP18K08065)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- heart failure, omega-3 polyunsaturated fatty acids, eicosapentaenoic acid, docosahexaenoic acid, cardioprotection, ventricular remodeling, myocardial fibrosis, anti-inflammatory activity, myocardial energy metabolism, cardiac ion channels, endothelial function, autonomic nervous system, GISSI-HF trial, cardiovascular mortality, hospitalization
- MeSH terms
- Animals, Cardiotonic Agents, Clinical Trials as Topic, Heart Failure, Humans, Fatty Acids, Omega-3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.